A Study of Asciminib Safety and Efficacy in Young Adults With Chronic Myeloid Leukemia in the Gulf Region (ASC4Young)
ASC4Young: Real-World Study of Asciminib Safety and Efficacy in Young Adults With Chronic Myeloid Leukemia in the Gulf Region
The aim of this study is to evaluate the real-world effectiveness and safety of asciminib among young adults with chronic myeloid leukemia (CML) across the Gulf region. The data source for this study will consist of routinely collected clinical information documented within the electronic health records (EHR) of participating centers.
研究概览
地位
条件
研究类型
注册 (估计的)
联系人和位置
学习联系方式
- 姓名:Novartis Pharmaceuticals
- 电话号码:+41613241111
- 邮箱:novartis.email@novartis.com
研究联系人备份
- 姓名:Novartis Pharmaceuticals
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
CML patients who initiate asciminib between 01 May 2023 and 31 May 2026 in participating centers across the Gulf region.
描述
Inclusion Criteria
- Confirmed diagnosis of Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP)
- Adult patients aged ≥ 18 years at the index date (or adult as defined by applicable national regulations)
- Documented exposure to asciminib during the identification period (May 2023 to May 2026)
- Provision of signed informed consent for secondary use of data, or an ethics committee-approved waiver of consent, where applicable (including for deceased patients or where data were previously collected within the EHR system)
Exclusion Criteria
- Patients who do not meet the eligibility criteria specified above
- Patients with insufficient medical record documentation to determine asciminib exposure or key study outcomes
学习计划
研究是如何设计的?
设计细节
- 观测模型:COHORT
- 时间观点:RETROSPECTIVE
队列和干预
团体/队列 |
|---|
|
Young Adults Cohort
CML patients aged ≤ 40 years at the first documented asciminib administration. |
|
Older Adults Cohort
CML patients aged > 40 years at the first documented asciminib administration. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Major Molecular Response (MMR) Rate in Young Adults
大体时间:Approximately 12 Months
|
MMR is defined as a BCR::ABL1 level on the International Scale (BCR::ABL1 IS) ≤ 0.1%. |
Approximately 12 Months
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Incidence of Adverse Events (AEs)
大体时间:Approximately 3, 6, and 12 months
|
Approximately 3, 6, and 12 months
|
|
|
Number of Treatment Interruptions Due to AEs
大体时间:Approximately 3, 6, and 12 months
|
Approximately 3, 6, and 12 months
|
|
|
Duration of Treatment Interruptions Due to AEs
大体时间:Approximately 3, 6, and 12 months
|
Approximately 3, 6, and 12 months
|
|
|
Time to Treatment Discontinuation due to Adverse Events (TTDAE)
大体时间:Approximately 3, 6, and 12 months
|
Approximately 3, 6, and 12 months
|
|
|
Proportion of Patients who Achieve an Early Molecular Response Milestone of BCR::ABL1 IS ≤ 10% After 3 Months of Treatment
大体时间:3 months
|
3 months
|
|
|
Proportion of Patients who Achieve an Early Molecular Response Milestone of BCR::ABL1 IS ≤ 1% After 6 Months of Treatment
大体时间:6 months
|
6 months
|
|
|
Number of Patients With Prior Tyrosine Kinase Inhibitor (TKI) Treatment
大体时间:Up to 12 months prior to Baseline
|
Up to 12 months prior to Baseline
|
|
|
Duration of CML at Time of Asciminib Treatment Initiation
大体时间:Baseline
|
Baseline
|
|
|
Asciminib Starting Dose
大体时间:Baseline
|
Baseline
|
|
|
Number of Treatment Interruptions
大体时间:Approximately 3, 6, and 12 months
|
Approximately 3, 6, and 12 months
|
|
|
Duration of Treatment Interruptions
大体时间:Approximately 3, 6, and 12 months
|
Approximately 3, 6, and 12 months
|
|
|
Number of Patients by Reasons for Treatment Interruptions and Subsequent Treatment Switching
大体时间:Approximately 3, 6, and 12 months
|
Approximately 3, 6, and 12 months
|
|
|
Number of Patients by Reason for Treatment Switch
大体时间:Approximately 3, 6, and 12 months
|
Approximately 3, 6, and 12 months
|
|
|
Number of Patients by Type and Severity of AEs
大体时间:Approximately 3, 6, and 12 months
|
Number of patients by type and severity of AEs including serious AEs and grade ≥ 3 AEs according to the Common Terminology Criteria for Adverse Events (CTCAE) v6.0. |
Approximately 3, 6, and 12 months
|
|
Incidence of AEs Leading to Dose Modifications
大体时间:Approximately 3, 6, and 12 months
|
Dose modifications include treatment interruptions and dose reductions. |
Approximately 3, 6, and 12 months
|
|
MMR in Patients Aged > 40 years
大体时间:Approximately 12 months
|
MMR is defined as BCR::ABL1 IS ≤ 0.1%. |
Approximately 12 months
|
|
Rate of Deep Molecular Response
大体时间:Approximately 12 months
|
Deep molecular response includes:
|
Approximately 12 months
|
|
Number of Patients With Dose Modifications
大体时间:Approximately 3, 6, and 12 months
|
Number of patients with dose modifications including up titration or dose reduction. |
Approximately 3, 6, and 12 months
|
|
Number of Patients by Clinicopathological Characteristics
大体时间:Up to 12 months pre-Baseline, Baseline, and approximately 3, 6 , and 12 months post-Baseline
|
Clinicopathological characteristics include:
|
Up to 12 months pre-Baseline, Baseline, and approximately 3, 6 , and 12 months post-Baseline
|
合作者和调查者
调查人员
- 研究主任:Novartis Pharmaceuticals、Novartis Pharmaceuticals
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.